Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
about
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationMetabolic factors and chronic hepatitis C: a complex interplayLipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomesAssociation of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infectionPredictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network.Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearanceComplementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.Effects of statins on the risk of hepatocellular carcinomaCoffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis CFluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.The impact of host factors on management of hepatitis C virus.Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Hepatitis C virus infection and nonalcoholic steatohepatitisImpact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.Status of essential trace minerals and oxidative stress in viral hepatitis C patients with nonalcoholic fatty liver diseaseDemographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north IndiaHepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.Chemoprevention for hepatocellular carcinoma: the role of statins.Individualization of chronic hepatitis C treatment according to the host characteristics.Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Unique ties between hepatitis C virus replication and intracellular lipids.Multifaceted roles for lipids in viral infection.Metabolic alterations and chronic hepatitis C: treatment strategies.New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials.Clinical perspective: statins and the liver--harmful or helpful?Lipids and HCV.Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortalityStatins and liver injury.Statin therapy in patients with cirrhosis.Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients.Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C InfectionThe impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis.
P2860
Q26779128-615CF029-1185-42A0-A8C6-CD1DAECF582AQ26864485-D8B658F1-EE60-4A5E-8849-C253DF62871BQ27011787-914F8187-D5DF-4BD5-B875-71B779E95D17Q28081216-B59C5E2C-3042-42DE-903C-5226D3BC4E46Q28534715-2C27158F-ADC4-4B92-9211-7C8E35FEDD05Q28543090-6A32ADF7-8B83-4C9C-AF94-E9F9F3D1033AQ30369757-DD9E7CBC-DDE4-4E5D-86E9-5E2A20535DB6Q33808119-B318D53C-40A9-4547-BC77-2AF10197EEA8Q34046758-A9A15752-263D-476E-B74B-362FCDCDC13FQ34177249-BD774BCC-E245-4EBC-8F19-A9B31CE24A30Q34997752-57F67ED5-CFEF-4374-91CF-79355C60E2C1Q35027939-9CE8AC42-44E8-4A76-8205-32E47EB1F83AQ35048926-4D1B014F-3CDE-4498-B95B-CA83D292BC67Q35122536-443E0456-08A1-46BF-9931-0276BD152D3FQ35990066-0CC1DE8D-CC67-49D1-9487-F8C4C9BD73CBQ36026554-0BAF52CA-3DCF-4DB0-B17E-19F126941ACCQ36179898-C5B37601-1A89-4BD7-AEF3-5AB7B1DD7A46Q36379566-662FE8C2-1C66-4143-AE1A-5ACAE0BEA2F5Q36457831-826A15F8-506A-436A-8551-F848EBBFE93CQ36800914-63C000AA-00CE-45DD-AB99-60DB47AFE98AQ36966151-C859FAEF-87A8-4558-A2A5-E27E668429DAQ37015738-0DC35D31-6D79-44FE-BB3B-DF68F876FA50Q37584611-9AF84B3C-E84D-4A98-B569-C0A2A75B3688Q37654502-AAE0C788-038C-411C-9FCA-9AE52D0AE4A2Q37699395-500AA876-1AE4-4E58-B9A6-B68B5E343D2CQ37865821-A90D97D0-A889-414E-8985-4612494C071AQ37870334-F71DF532-335F-4C45-AA14-C462C4DB440FQ37924816-9D7C1787-8A30-48B5-8110-1AC5631F2BD5Q37993889-5F1DD5E4-4225-4894-8322-DDD84956B0BEQ38009719-9014597B-34B2-497F-9D5A-833F0870C1B9Q38056643-8AE6216D-6AF3-4815-BD59-9AD1106930B8Q38134774-57489301-E3EF-420C-B2C9-99DF1B8000DFQ38170504-9E57D62D-B0F2-411C-881D-1101889AA965Q38198618-97A7D2BB-66B6-43E4-94A8-6754399567CBQ38204369-51ECCAFB-0091-48D0-B34A-6BBCC1BCF95DQ38608978-93B08ADF-DDFD-4B57-99BA-65BE73B91BA0Q38961331-B9AFB7FC-36CF-46B9-94F6-60517946238EQ40707628-66DBE580-66CE-4D25-B203-4058447888FDQ41435455-00A244AC-8448-46F6-9BC4-5EB621B61AA4Q42211503-A2BBE0E0-A380-488D-BFD2-86BE7D64EB4C
P2860
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@en
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@nl
type
label
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@en
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@nl
prefLabel
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@en
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@nl
P2093
P2860
P356
P1433
P1476
Serum cholesterol and statin u ...... erferon and ribavirin therapy.
@en
P2093
Clifford A Brass
Dawn M Torres
Hans Tillmann
Janice K Albrecht
John G McHutchison
Kenneth Koury
Keyur Patel
Lorenzo Rossaro
Mark S Sulkowski
P2860
P304
P356
10.1002/HEP.23787
P407
P577
2010-09-01T00:00:00Z